Fighting Cerebral Malaria

  • Author: Melania Tesio
  • Published: 22 March 2014
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
  • Source / Publisher: PLoS Pathogens/Public Library of Science
thumbnail image: Fighting Cerebral Malaria

Cerebral malaria is the most severe form of malaria, an infectious disease caused by the parasite Plasmodium falciparum, and is lethal in most cases. Moreover, in surviving patients, it causes long-lasting cognitive and neurological disabilities, such as epilepsy and learning disorders.

Kevin C. Kain, University Health Network (UHN), Toronto, Canada, and co-workers discovered that rogislitazone (pictured), a drug already approved for the treatment of diabetes, prevents the neurological impairment associated with cerebral malaria. By using a mouse model of this disease, the researchers demonstrated that when rogislitazone is administered together with anti-malaric compounds, it prevents the development of brain abnormalities. As a consequence, rogislitazone improved the survival of mice affected by cerebral malaria and protected them from neurological impairment.
Rogislitazone may thus be a valuable tool to prevent and treat cerebral malaria.

Article Views: 2572

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

If you would like to reuse any content, in print or online, from, please contact us first for permission and consult our permission guidance prior to making your request

Follow on Facebook Follow on Twitter Follow on YouTube Follow on LinkedIn Follow on Instagram RSS Sign up for newsletters

Magazine of Chemistry Europe (16 European Chemical Societies) published by Wiley-VCH